JP2023520004A5 - - Google Patents

Info

Publication number
JP2023520004A5
JP2023520004A5 JP2022559750A JP2022559750A JP2023520004A5 JP 2023520004 A5 JP2023520004 A5 JP 2023520004A5 JP 2022559750 A JP2022559750 A JP 2022559750A JP 2022559750 A JP2022559750 A JP 2022559750A JP 2023520004 A5 JP2023520004 A5 JP 2023520004A5
Authority
JP
Japan
Prior art keywords
aripiprazole
formulation according
patient
formulation
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022559750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520004A (ja
JP7733000B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2021/014194 external-priority patent/WO2021201239A1/en
Publication of JP2023520004A publication Critical patent/JP2023520004A/ja
Publication of JP2023520004A5 publication Critical patent/JP2023520004A5/ja
Priority to JP2025137577A priority Critical patent/JP2025176037A/ja
Application granted granted Critical
Publication of JP7733000B2 publication Critical patent/JP7733000B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022559750A 2020-04-01 2021-04-01 アリピプラゾール治療の投薬開始のための方法 Active JP7733000B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025137577A JP2025176037A (ja) 2020-04-01 2025-08-21 アリピプラゾール治療の投薬開始のための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063003544P 2020-04-01 2020-04-01
US63/003,544 2020-04-01
PCT/JP2021/014194 WO2021201239A1 (en) 2020-04-01 2021-04-01 Methods for dose initiation of aripiprazole treatments

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025137577A Division JP2025176037A (ja) 2020-04-01 2025-08-21 アリピプラゾール治療の投薬開始のための方法

Publications (3)

Publication Number Publication Date
JP2023520004A JP2023520004A (ja) 2023-05-15
JP2023520004A5 true JP2023520004A5 (cg-RX-API-DMAC7.html) 2025-05-21
JP7733000B2 JP7733000B2 (ja) 2025-09-02

Family

ID=75581573

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2022559751A Active JP7584535B2 (ja) 2020-04-01 2021-04-01 アリピプラゾール注射用調製物を投与する方法
JP2022559750A Active JP7733000B2 (ja) 2020-04-01 2021-04-01 アリピプラゾール治療の投薬開始のための方法
JP2024193628A Active JP7891516B2 (ja) 2020-04-01 2024-11-05 アリピプラゾール注射用調製物を投与する方法
JP2025137577A Pending JP2025176037A (ja) 2020-04-01 2025-08-21 アリピプラゾール治療の投薬開始のための方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022559751A Active JP7584535B2 (ja) 2020-04-01 2021-04-01 アリピプラゾール注射用調製物を投与する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024193628A Active JP7891516B2 (ja) 2020-04-01 2024-11-05 アリピプラゾール注射用調製物を投与する方法
JP2025137577A Pending JP2025176037A (ja) 2020-04-01 2025-08-21 アリピプラゾール治療の投薬開始のための方法

Country Status (16)

Country Link
US (6) US20230129919A1 (cg-RX-API-DMAC7.html)
EP (3) EP3941470A1 (cg-RX-API-DMAC7.html)
JP (4) JP7584535B2 (cg-RX-API-DMAC7.html)
KR (3) KR20240165486A (cg-RX-API-DMAC7.html)
CN (3) CN115397420A (cg-RX-API-DMAC7.html)
AU (2) AU2021248212A1 (cg-RX-API-DMAC7.html)
BR (2) BR112022018721A2 (cg-RX-API-DMAC7.html)
CA (3) CA3163321C (cg-RX-API-DMAC7.html)
ES (1) ES2995466T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241574T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069157T2 (cg-RX-API-DMAC7.html)
MX (2) MX2022012354A (cg-RX-API-DMAC7.html)
PL (1) PL4125903T3 (cg-RX-API-DMAC7.html)
TW (4) TWI865760B (cg-RX-API-DMAC7.html)
WO (2) WO2021201238A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202210633B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
US20230129919A1 (en) 2020-04-01 2023-04-27 Otsuka Pharmaceutical Co., Ltd. Methods for dose initiation of aripiprazole treatments
WO2024194955A1 (en) 2023-03-17 2024-09-26 Otsuka Pharmaceutical Co., Ltd. Methods of dispersing aripiprazole injectable preparations
CN120957722A (zh) 2023-04-26 2025-11-14 大塚制药株式会社 用阿立哌唑治疗精神分裂症或i型双相障碍的剂量启动

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
BRPI0415531B8 (pt) * 2003-10-23 2021-05-25 Otsuka Pharma Co Ltd formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
KR101892745B1 (ko) 2007-06-25 2018-08-28 오쓰까 세이야꾸 가부시키가이샤 코어/셀 구조를 가진 미소구
CA2655335C (en) 2007-12-19 2016-09-06 Janssen Pharmaceutica N.V. Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
US10525057B2 (en) * 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
KR20200010320A (ko) 2017-05-16 2020-01-30 보우 리버 엘엘씨 치료 방법
AU2019230014B2 (en) * 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN108498456B (zh) 2018-05-16 2021-01-01 丽珠医药集团股份有限公司 一种阿立哌唑缓释微球及其制备方法
CN110327296B (zh) 2019-08-06 2021-10-22 深圳市泛谷药业股份有限公司 一种阿立哌唑长效注射制剂及其制备方法
US20230129919A1 (en) 2020-04-01 2023-04-27 Otsuka Pharmaceutical Co., Ltd. Methods for dose initiation of aripiprazole treatments

Similar Documents

Publication Publication Date Title
Wedemeyer et al. Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection
JP2021066744A5 (ja) ブプロピオンおよびデキストロメトルファンを含む組成物
JP2015187125A5 (cg-RX-API-DMAC7.html)
JP2013509435A5 (cg-RX-API-DMAC7.html)
IL278717B1 (en) Starting dose of pth conjugates
JP2023517535A5 (cg-RX-API-DMAC7.html)
JP2024501919A5 (cg-RX-API-DMAC7.html)
PH12021553056A1 (en) Modified release formulations and uses thereof
Sands et al. P492 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: a phase 3, randomized, placebo-controlled study: results of the LIBERTY-UC study
HRP20241574T1 (hr) Metode za početak doziranja liječenja aripiprazolom
KR20120023754A (ko) Ave8062 및 소라페닙을 포함하는 항종양 조합물
JP2016505050A5 (cg-RX-API-DMAC7.html)
JP2023109829A5 (cg-RX-API-DMAC7.html)
MX2022002555A (es) Conjugados de farmaco de anticuerpo de union a receptor de tipo ii de la hormona anti-mulleriana humana (amhrii) y uso de los mismos en el tratamiento de canceres.
JP2007501806A5 (cg-RX-API-DMAC7.html)
JP2021535163A5 (cg-RX-API-DMAC7.html)
TW200808327A (en) Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma
FI3359572T3 (fi) Menetelmä multippeliskleroosin hoitamiseksi
JP2009539916A5 (cg-RX-API-DMAC7.html)
MX2023005431A (es) Composicion farmaceutica, formulacion farmaceutica combinada, y kit de formulacion combinada para la prevencion o el tratamiento de la hepatitis b cronica, cada uno que comprende, como ingrediente activo, un agente antiviral oral y una vacuna terapeutica que incluye un lipopeptido y un adyuvante de poli(i:c).
JP2005529152A5 (cg-RX-API-DMAC7.html)
RU2018144248A (ru) Схемы дозирования вортиоксетина для быстрого появления антидепрессивного эффекта
JP2015515971A5 (cg-RX-API-DMAC7.html)
JP2005509663A5 (cg-RX-API-DMAC7.html)
CN107519171A (zh) 洛匹那韦减轻伊立替康毒性的医药新用途